Advertisement

International Journal of Hematology

, Volume 83, Issue 2, pp 164–178 | Cite as

Current Status of Hematopoietic Cell Transplantation for Adult Patients with Hematologic Diseases and Solid Tumors in Japan

  • Masahiro Imamura
  • Shigetaka Asano
  • Mine Harada
  • Yasuo Ikeda
  • Koji Kato
  • Shunichi Kato
  • Keisei Kawa
  • Seiji Kojima
  • Yasuo Morishima
  • Yoshihisa Morishita
  • Tatsutoshi Nakahata
  • Jun Okamura
  • Shinichiro Okamoto
  • Shintaro Shiobara
  • Mitsune Tanimoto
  • Masahiro Tsuchida
  • Yoshiko Atsuta
  • Kazuhito Yamamoto
  • Junji Tanaka
  • Nobuyuki Hamajima
  • Yoshihisa Kodera
Article

Abstract

A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation.The 10-year overall survival (OS) rates after HCT for each disease are as follows: acute myelogenous leukemia, 44.2%; acute lymphocytic leukemia, 33.7%; adult T-cell leukemia, 24.6%; chronic myelogenous leukemia, 53.3%; myelodysplastic syndrome, 37.3%; non-Hodgkin’s lymphoma, 41.5%; Hodgkin’s lymphoma, 50.8%; aplastic anemia, 72.5%; breast cancer, 37.1%; germ cell tumor, 52.6%; and ovarian cancer, 44.2%.The 5-year OS rates for multiple myeloma and lung cancer were 40.6% and 23.6%, respectively. Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients.The respective frequencies of acute graft-versus-host disease (GVHD) and chronic GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation. OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type.These data provide objective and valuable information for hematologists as well as for patients who need HCT.

Key words

Hematopoietic cell transplantation Overall survival Hematologic malignancies Solid tumors Graft-versus-host disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thomas ED. Bone marrow transplantation: a review. Semin Hematol. 1999;36(suppl 7):95–103.Google Scholar
  2. 2.
    Craddock C. Haematopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol. 2000;1:227–234.CrossRefGoogle Scholar
  3. 3.
    Nieto Y, Jones RB, Shpall EL. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004;26:31–56.CrossRefGoogle Scholar
  4. 4.
    Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005;36:575–590.CrossRefGoogle Scholar
  5. 5.
    Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 2000;111:6–17.CrossRefGoogle Scholar
  6. 6.
    Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood. 2003;102:1541–1547.CrossRefGoogle Scholar
  7. 7.
    Izutsu K, Kanda Y, Ohno H, et al. Unrelated bone marrow transplantation from non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood. 2004;103:1955–1960.CrossRefGoogle Scholar
  8. 8.
    Kameoka I, Kami M, Takahashi S, et al. Clinical impact of graftversus- host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Bone Marrow Transplant. 2004;34:711–719.CrossRefGoogle Scholar
  9. 9.
    Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88:795–802.PubMedGoogle Scholar
  10. 10.
    Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586–3592.CrossRefGoogle Scholar
  11. 11.
    Madrigal JA, Cohen SB, Gluckman E, Charron DJ. Does cord blood transplantation result in lower graft-versus-host disease? It takes more than two to tango. Hum Immunol. 1997;56:1–5.CrossRefGoogle Scholar
  12. 12.
    Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252–2256.PubMedGoogle Scholar
  13. 13.
    Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177–1185.CrossRefGoogle Scholar
  14. 14.
    Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606–1613.PubMedGoogle Scholar
  15. 15.
    Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–4206.CrossRefGoogle Scholar
  16. 16.
    Zittoun RA, Mandelli F, Willemze R, et al, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Research Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332:217–223.CrossRefGoogle Scholar
  17. 17.
    Burnett AK, Goldstone AH, Stevens RMF, et al, for the UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Randomised comparison of addition of autologous bonemarrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700–708.CrossRefGoogle Scholar
  18. 18.
    Cassileth PA, Harrington DP,Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1666.CrossRefGoogle Scholar
  19. 19.
    Gondo H, Harada M, Miyamoto T, et al. Autologous peripheral stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1997;20:821–826.CrossRefGoogle Scholar
  20. 20.
    Thomas X, Boiron J-M, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–4086.CrossRefGoogle Scholar
  21. 21.
    Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–2825.CrossRefGoogle Scholar
  22. 22.
    Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2004;10:195–203.CrossRefGoogle Scholar
  23. 23.
    Gorin NC. Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells. 2002;20:3–10.CrossRefGoogle Scholar
  24. 24.
    Druker BJ, O’Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2002;1:111–135.CrossRefGoogle Scholar
  25. 25.
    Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17(suppl 3):S5-S6.PubMedGoogle Scholar
  26. 26.
    Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors of patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968.CrossRefGoogle Scholar
  27. 27.
    Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med. 2001;110:339–346.CrossRefGoogle Scholar
  28. 28.
    Appelbaum FR, Anderson A. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(suppl 1):S25-S29.CrossRefGoogle Scholar
  29. 29.
    Runde V, de Witte T, Arnold R, et al, on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255–261.CrossRefGoogle Scholar
  30. 30.
    Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;200:1997–2004.Google Scholar
  31. 31.
    Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–1951.CrossRefGoogle Scholar
  32. 32.
    Bacigalupo A, Hows J, Gordon-Smith EC, et al. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant. 1998;3:531–535.Google Scholar
  33. 33.
    Hows JM, Szydlo R, Anasetti C, et al. Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant. 1992;10:102–106.PubMedGoogle Scholar
  34. 34.
    Keran NA, Bartsh G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602.CrossRefGoogle Scholar
  35. 35.
    Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803.CrossRefGoogle Scholar
  36. 36.
    Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515–3520.PubMedGoogle Scholar
  37. 37.
    Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103:2490–2497.CrossRefGoogle Scholar
  38. 38.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545.CrossRefGoogle Scholar
  39. 39.
    Vose J. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(suppl 1):S1-S3.CrossRefGoogle Scholar
  40. 40.
    Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy in Aggressive Non- Hodgkin’s Lymphomas: report of the jury. J Clin Oncol. 1999;17:423–429.CrossRefGoogle Scholar
  41. 41.
    Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205–213.CrossRefGoogle Scholar
  42. 42.
    Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non- Hodgkin’s lymphoma. Ann Oncol. 2003;14:737–744.CrossRefGoogle Scholar
  43. 43.
    Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2001;23:4314–4321.CrossRefGoogle Scholar
  44. 44.
    Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–578.CrossRefGoogle Scholar
  45. 45.
    Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease: European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291–1296.CrossRefGoogle Scholar
  46. 46.
    Cunningham DH, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12:759–763.CrossRefGoogle Scholar
  47. 47.
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97.CrossRefGoogle Scholar
  48. 48.
    Child J, Morgan G, Davies F, et al, for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.CrossRefGoogle Scholar
  49. 49.
    Bensinger W, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol. 2001;38:243–249.CrossRefGoogle Scholar
  50. 50.
    Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793.PubMedGoogle Scholar
  51. 51.
    Bardos A, Barlogie B, Siegel E, et al. Improved outcome of nonmyeloablative allogeneic transplantation in multiple myeloma. J Clin Oncol. 2002;20:1295–1303.CrossRefGoogle Scholar
  52. 52.
    Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografting for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454.CrossRefGoogle Scholar
  53. 53.
    Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20–32.CrossRefGoogle Scholar
  54. 54.
    Childs R, Chemoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N Engl J Med. 2000;343:750–758.CrossRefGoogle Scholar
  55. 55.
    Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829–3836.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Masahiro Imamura
    • 1
  • Shigetaka Asano
    • 2
  • Mine Harada
    • 3
  • Yasuo Ikeda
    • 4
  • Koji Kato
    • 5
  • Shunichi Kato
    • 6
  • Keisei Kawa
    • 7
  • Seiji Kojima
    • 8
  • Yasuo Morishima
    • 9
  • Yoshihisa Morishita
    • 10
  • Tatsutoshi Nakahata
    • 11
  • Jun Okamura
    • 12
  • Shinichiro Okamoto
    • 4
  • Shintaro Shiobara
    • 13
  • Mitsune Tanimoto
    • 14
  • Masahiro Tsuchida
    • 15
  • Yoshiko Atsuta
    • 16
  • Kazuhito Yamamoto
    • 9
  • Junji Tanaka
    • 1
  • Nobuyuki Hamajima
    • 16
  • Yoshihisa Kodera
    • 17
  1. 1.Department of Hematology and OncologyHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Consolidated Research Institute for Advanced Science and Medical CareWaseda UniversityTokyo
  3. 3.Department of Medicine and Biosystemic ScienceKyushu University Graduate School of MedicineFukuoka
  4. 4.Division of Hematology, Department of Internal MedicineKeio University School of MedicineTokyo
  5. 5.Division of Hematology and Oncology, Children’s Medical Center, Red CrossNagoya First HospitalNagoya
  6. 6.Department of Cell Transplantation and Regenerative MedicineTokai University School of MedicineKanagawa
  7. 7.Department of PediatricsOsaka Medical Center and Research Institute for Maternal and Child HealthOsaka
  8. 8.Department of Pediatrics and Developmental PediatricsNagoya University Graduate School of MedicineNagoya
  9. 9.Department of Hematology and Cell TherapyAichi Cancer Center HospitalNagoya
  10. 10.Department of Hematology and OncologyJA Aichi Showa HospitalAichi
  11. 11.Department of PediatricsGraduate School of Medicine, Kyoto UniversityKyoto
  12. 12.Institute for Clinical ResearchNational Kyushu Cancer CenterFukuoka
  13. 13.Department of Cellular Transplantation BiologyKanazawa University Graduate School of MedicineKanazawa
  14. 14.Department of Hematology and OncologyOkayama University Graduate School of Medicine and DentistryOkayama
  15. 15.Department of PediatricsIbaragi Children’s HospitalIbaragi
  16. 16.Department of Preventive Medicine/Biostatistics and Medical Decision MakingNagoya University Graduate School of MedicineNagoya
  17. 17.Department of HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan

Personalised recommendations